Skip to main content
. 2021 Dec 13;118(51):e2114126118. doi: 10.1073/pnas.2114126118

Fig. 2.

Fig. 2.

ORP5 and/or ORP8 KD inhibits tumor growth of KRAS-mutant PDAC in vivo. Monoclonal shORP5, shORP8, and shORP5/8 KD MiaPaCa-2 and BxPC-3 cells were injected subcutaneously in the left flanks of nu/nu-immunosuppressed mice. Monoclonal empty vector controls (CN) were injected in the right flanks to serve as internal controls. Tumors were harvested after 6 to 8 wk (one-way ANOVA, ***P < 0.005; n = 8 per group). ns, nonsignificant.